|
On the Risk of Nitrosamine Contamination during blister packaging
|
|
2
|
774
|
August 10, 2023
|
|
Anybody inquired about Nitrosamines in Poly bags?
|
|
6
|
1060
|
August 5, 2023
|
|
N-Nitroso Betahistine formation
|
|
2
|
475
|
July 28, 2023
|
|
Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies
|
|
3
|
816
|
July 26, 2023
|
|
Nitrosamines and bioequivalence studies
|
|
4
|
596
|
July 20, 2023
|
|
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals
|
|
16
|
2378
|
July 3, 2023
|
|
Low Nitrite Excipients - it’s happening
|
|
2
|
794
|
June 30, 2023
|
|
Nitrosamine Risk Assessment for Drug Product Manufacturer with 50+ APIs
|
|
4
|
553
|
May 4, 2023
|
|
Instem SOT 2023 Presentation on Assessing N-nitrosamines Potency Classes
|
|
1
|
572
|
May 2, 2023
|
|
A Consideration of the Extent That Tertiary Amines Can Form N-Nitroso Dialkylamines in Pharmaceutical Products
|
|
1
|
989
|
April 25, 2023
|
|
NDMA formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product
|
|
0
|
684
|
March 24, 2023
|
|
Nitrosamines in topical products
|
|
3
|
880
|
March 9, 2023
|
|
Formation of Dialkyl-N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation
|
|
6
|
1020
|
February 25, 2023
|
|
Anybody has working with a Gliclazide nitrosamine?
|
|
3
|
923
|
February 14, 2023
|
|
IPEC Europe announces the availability of the revised “Questionnaire for Excipient Nitrosamines Risk Evaluation” (Version 4, 2022)
|
|
11
|
1297
|
February 14, 2023
|
|
Lhasa Tutorial Vid on new Mirabilis 4.0
|
|
2
|
461
|
January 31, 2023
|
|
What to do with Nitrite content reported by Excipients?
|
|
0
|
585
|
January 25, 2023
|
|
What's your experience on API risk assessments?
|
|
4
|
473
|
November 25, 2022
|
|
Checklist for EMA Q&A Q4
|
|
0
|
424
|
July 30, 2022
|
|
Fate purge study
|
|
0
|
344
|
July 14, 2022
|
|
Sufficient AMES test, parameters
|
|
6
|
941
|
July 13, 2022
|
|
Como conducir El Análisis de Riesgo?
|
|
0
|
314
|
May 9, 2022
|
|
What is the probability of nitrosamine formation during DP production
|
|
6
|
498
|
April 26, 2022
|
|
200+ USP Monograph w/ Tertiary amines
|
|
1
|
397
|
April 5, 2022
|
|
How Relevant is a 'check list'?
|
|
0
|
231
|
March 2, 2022
|
|
FDA Warning letter <Nitrosamine or NOT>
|
|
0
|
350
|
February 14, 2022
|
|
Update of the CMDh's Q&A Document on Nitrosamine Impurities
|
|
2
|
641
|
January 26, 2022
|
|
Nitrosamine Workshop USP / Sindusfarma / ANF ACFB -live discussion
|
|
7
|
793
|
December 8, 2021
|
|
When minimum information is provided for risk assessment?
|
|
1
|
244
|
November 23, 2021
|
|
Screening vs **Risk Assessment**?
|
|
11
|
455
|
September 7, 2021
|